Jonathan Hepple is a co-founder and Director of Rosetta Capital. He has more than 20 years’ investment experience in the life sciences industry. His previous roles include Founder and Director of BioScience Managers and Investment Analyst at Rothschild Asset Management. He was also a Partner at Seroba Life Sciences, where he was on the Boards of Covagen and Opsona.

An experienced  Non-Executive Director, Jonathan has held Board roles and is actively engaged in portfolio companies such as Catalyst Biosciences, GlycoMimetics, Novimmune, Procertus and Tranzyme, and also has worked closely with GeminX, Polyphor and Zealand. He currently serves on the Boards of Aprea and Clanotech.

Jonathan holds a PhD in Cancer Research from the University of Cambridge and a Bachelor’s degree in Biology from the University of Oxford.